Key Points Oncolytics has secured a new patent in several countries covering pelareorep’s use as a cancer immunotherapy, with a corresponding U.S. patent expected soon….
October 13, 2026
At EHA 2026 this month, Legend Biotech (NASDAQ: LEGN) is presenting early data on LB2501, an in vivo CAR-T therapy that builds CAR-T cells inside…
April 07, 2026
Greenwich LifeSciences Files New GP2 Patent Claims That Could Double Its Breast Cancer Market
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has filed new patent claims for its breast cancer immunotherapy GLSI‑100 (GP2 + GM‑CSF), based on statistically significant immune‑response and recurrence‑rate…
December 17, 2025
Oncolytics Biotech Reports Encouraging Data for Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Oncolytics Biotech Inc. (NASDAQ: ONCY) has released new clinical and translational data supporting the potential of its lead immunotherapy candidate, pelareorep, in second-line metastatic colorectal…